Healthcare & Medical Devices Global On demand · 24-48h

Global KRAS Inhibitor Market Strategic Research Report

Global KRAS Inhibitor Market Strategic Research Report
$3,500 USD
Market Research Reports
Strategic Research Report
Global KRAS Inhibitor Market
$1412025
8.6%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Lung Cancer, Pancreatic Cancer, Colorectal Cancer, Others

By Application: Clinic Laboratories, Cancer Diagnostic Centres, Hospitals, Others

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Amgen, Boehringer Ingelheim, BridgeBio Pharma, Erasca, Innovent Biologics, Incyte, Mirati Therapeutics, Novartis, Jemincare, Cardiff Oncology

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 100 pages
Market size 2025
$141
Million USD
Forecast CAGR
8.6%
2025-2032
Forecast 2032
$251.2
Projected
区域
5
Asia Pacific · Latin America · MEA · Europe · North America

概述

Scope of the Report

The global KRAS Inhibitor market size is predicted to grow from US$ 141 million in 2025 to US$ 249 million in 2032; it is expected to grow at a CAGR of 8.6% from 2026 to 2032.

KRAS inhibitors are a class of targeted cancer therapies designed to block the activity of the KRAS protein, a common driver of cancer, particularly in pancreatic, colorectal, and lung cancers. KRAS mutations are notoriously difficult to target because the protein has a smooth surface with few pockets for drug binding. However, recent advances have led to the development of specific inhibitors, such as sotorasib and adagrasib, which target the G12C mutation in KRAS, a mutation present in a subset of cancers. These inhibitors work by irreversibly binding to the mutant KRAS protein, preventing it from signaling the uncontrolled cell growth that leads to cancer. While these drugs have shown promise, they are not universally effective, and resistance often develops, leading to ongoing research to improve their efficacy and expand their use to other KRAS mutations.

Global key KRAS Inhibitor players cover Amgen, Boehringer Ingelheim, BridgeBio Pharma, Erasca, Innovent Biologics, etc.

Key Questions Addressed in this Report

What is the 10-year outlook for the global KRAS Inhibitor market?

What factors are driving KRAS Inhibitor market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do KRAS Inhibitor market opportunities vary by end market size?

How does KRAS Inhibitor break out by Type, by Application?

This report presents a comprehensive overview of the global KRAS Inhibitor market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Lung Cancer
  • Pancreatic Cancer
  • Colorectal Cancer
  • Others

Segment by Application

  • Clinic Laboratories
  • Cancer Diagnostic Centres
  • Hospitals
  • Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global KRAS Inhibitor market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Clinic Laboratories, Cancer Diagnostic Centres, Hospitals evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global KRAS Inhibitor Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 8.6%
Regional growth momentum
Market share by segment
Key metrics
Base value
$141
2025
Forecast
$251.2
2032
CAGR
8.6%
2025–2032
区域
5
global
Key companies
AmgenBoehringer IngelheimBridgeBio PharmaErascaInnovent BiologicsIncyteMirati TherapeuticsNovartis
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Lung CancerPancreatic CancerColorectal CancerOthers
By Application
Clinic LaboratoriesCancer Diagnostic CentresHospitalsOthers

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Lung Cancer
  • 3.1.3 Pancreatic Cancer
  • 3.1.4 Colorectal Cancer
  • 3.1.5 Others
  • 3.1.6 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Clinic Laboratories
  • 4.1.3 Cancer Diagnostic Centres
  • 4.1.4 Hospitals
  • 4.1.5 Others
  • 4.1.6 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Amgen
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Boehringer Ingelheim
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 BridgeBio Pharma
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Erasca
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 Innovent Biologics
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Incyte
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Mirati Therapeutics
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 Novartis
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 Jemincare
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Cardiff Oncology
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

What is the size of the global KRAS Inhibitor market?
The global KRAS Inhibitor market is estimated at US$ 141 million in 2025 (base year) and is projected to reach US$ 249 million by 2032.
What is the forecast CAGR for the KRAS Inhibitor market?
The market is expected to grow at a CAGR of 8.6% from 2026 to 2032, expanding from US$ 141 million in 2025 to US$ 249 million in 2032, roughly 1.8 times its base-year value.
What is KRAS Inhibitor?
KRAS inhibitors are a class of targeted cancer therapies designed to block the activity of the KRAS protein, a common driver of cancer, particularly in pancreatic, colorectal, and lung cancers. KRAS mutations are notoriously difficult to target because the protein has a smooth surface with few pockets for drug binding. However, recent advances have led to the development of specific inhibitors, such as sotorasib and adagrasib, which target the G12C mutation in KRAS, a mutation present in a subset of cancers.
How is the KRAS Inhibitor market segmented by type?
By type, the market is segmented into Lung Cancer, Pancreatic Cancer, Colorectal Cancer and Others.
What are the key applications of KRAS Inhibitor?
Key applications covered include Clinic Laboratories, Cancer Diagnostic Centres, Hospitals and Others.
Which companies are profiled in the KRAS Inhibitor market report?
Key players profiled include Amgen, Boehringer Ingelheim, BridgeBio Pharma, Erasca, Innovent Biologics, Incyte, Mirati Therapeutics and Novartis, among 10 companies covered in total.
What geographies does the KRAS Inhibitor market analysis include?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What are the key demand drivers for KRAS Inhibitor?
What factors are driving KRAS Inhibitor market growth, globally and by region?
Who should buy the KRAS Inhibitor market report?
The report is intended for manufacturers and solution providers, distributors and end users in Clinic Laboratories, Cancer Diagnostic Centres and Hospitals, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the KRAS Inhibitor market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

All data sources are cited within the report. View our full research methodology →
Select a license
from US$3,500.00
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.